Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

Attempts at developing an effective therapy for PWS, and the abnormal desire for food associated with the rare disorder, have been fruitless but Levo Therapeutics' enthusiasm for LV-101 remains high, despite a Phase III setback.

Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.